The Europe Osteoporosis Drugs Market would witness market growth of 4% CAGR during the forecast period (2020-2026).
Growth in the market for osteoporosis drugs is likely to be delayed due to side effects and risks involved with osteoporosis medications. For eg, heartburn, muscle and joint pain, diarrhea, and stomach or esophagus ulcers are risks associated with the drug class of bisphosphonates. Other than this, other classes of drugs also have side effects in patients. Many risks caused by osteoporosis medications include bone trauma, bone breaks, and urinary infection. Moreover, the patent expiry of new branded products and the restricted reimbursement by healthcare payers often adversely affect the growth of the market.
Rank ligand inhibitors may also be used in conjunction with other drugs to give a synergistic effect on the overall treatment regimen. It is also anticipated that this factor will be one of the key factors responsible for presenting lucrative opportunities. Other advantages related to ligand rank Inhibitors such as decreased bone cell turnover and increased bone mineral density, resulting in high demand.
The major factor contributing to the growth of the market for osteoporosis drugs is the increase in the prevalence of osteoporosis. In addition, other reasons that fuel the growth of the osteoporosis drugs market are the rise for the geriatric population worldwide and the rise in sedentary lifestyles worldwide. However, the adverse effects of osteoporosis medications and the time-consuming medication development procedure impede the expansion of the demand for osteoporosis medicines. Conversely, strong growth potential in developed economies is projected to generate attractive prospects over the forecast period.
Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company
Scope of the Study
Market Segmentation:
By Route of Administration

  • Oral
  • Injectable and
  • Other Route of Administration


By Drug Class

  • Bisphosphonates
  • Rank Ligand Inhibitors
  • Parathyroid Hormone Therapy
  • Calcitonin
  • Selective Estrogen Inhibitors Modulator (SERM) and
  • Other Drug Classes


By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe


Companies Profiled

  • Amgen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • Allergan PLC
  • Eli Lilly and Company


Unique Offerings from KBV Research

  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free